Topical Ivermectin + Metrogel from Galderma

Written by on November 16, 2011 in Demodex Mites, Galderma, interviews, Ivermectin, Metrogel 1%, patents with 1 Comment

An update to the 2009 filing of the patent covering preparations of Ivermectin and Metronidazole has emerged at the USPTO Patent Application Site. That application was in turn a followup to the original French language application 0505918 from 2005.

The patent covers many different combinations of ivermectin and metronidazole such as emulsion, cream, gel with ivermectin present in an amount of from 0.01% to 5% by weight and metronidazole is present in an amount of from 0.01% to 2% by weight.

Additional agents, claimed to be beneficial include “antibiotics, anti-bacterial agents, anti-viral agents, anti-parasitic agents, anti-fungal agents, anaesthetics, analgesics, anti-allergic agents, retinoids, free-radical scavengers, anti-pruritic agents, keratolytic agents, anti-seborrhoeic agents, anti-histamines, sulfides, and immunosuppressant or anti-proliferative products”.

Patents already exist that cover Ivermectin to treat demodex mites and also to indirectly treat rosacea. Galderma’s patent, if granted will cover the combination of Topical Avermectins and Metrondizole to treat rosacea.

A New Product Coming?

It is impossible to tell just from a patent application whether a company is actually pursing development of a related product.

We do know that Galderma a leading investor in dermatology research and development. If any company is able to progress a product from invention to approval, it is Galderma.

Personally I would like to see some solid clinical trials with topical products that contain ivermectin. Only then will we see exactly which rosacea sufferers will respond to this sort of treatment.

I would feel a bit nervous about using a product that only a vet would normally prescribe – so solid clinical data on ivermectin could only be a good thing.

Updated Patent Application

United States Patent Application 20110274631

KAOUKHOV; Alexandre ;   et al., GALDERMA S.A., November 10, 2011

France Filing Date: Jun 10, 2005, Application Number 0505918


Pharmaceutical/dermatological compositions containing at least one avermectin compound, e.g., ivermectin and metronidazole or salt, ester or derivative thereof, are useful for treating afflictions of the skin, especially rosacea.

1. A regime or regimen for treating rosacea, comprising topically applying onto the afflicted skin area of an individual in need of such treatment, a pharmaceutical/dermatological topically applicable composition comprising anti-rosacea effective amounts of ivermectin and metronidazole, formulated into a topically applicable, physiologically acceptable medium therefor.

Related Articles

About the Author

About the Author: David Pascoe started the Rosacea Support Group in October 1998. .

Follow Rosacea Support

Subscribe via RSS Feed

1 Reader Comment

  1. Rob says:

    When later this year? Would be nice to be able to get it this summer.

Leave your comment here


Discover more from Rosacea Support Group

Subscribe now to keep reading and get access to the full archive.

Continue reading

Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.